DNA Repair Drugs Market to Surpass US$ 8,378.1 Million by 2026- Coherent Market Insights
![]() |
DNA Repair Drugs |
DNA damage is an aberrant DNA structure that causes changes
to the genetic material's structure and hinders the replication mechanism from
working properly. A cell uses a mechanism called DNA repair to detect and
repair damage to the DNA molecules that encode its genome.
One of the biggest
causes of death worldwide is cancer. Numerous cancer disorders affect a big
number of people. As a result, the global market for DNA
Repair Drugs Market is
projected to grow as the incidence of cancer among the population rises. For
instance, the World Health Organization estimates that there were 9.6 million
cancer-related deaths and 18.1 million new cases worldwide in 2018.
The Global DNA Repair Drugs Market Size Was Valued At US$ 461.3 Mn In 2017, And Is Expected To Exhibit A CAGR Of 32.4% Over The Forecast Period (2018–2026).
Additionally, it is projected that increased demand and the adoption of next-generation technologies will propel the market. Several important firms are investing in research and development and implementing initiatives to create new products. The DNA Repair Drugs Market is expected to rise as a result of this issue. For instance, BRISTOL-MYERS SQUIBB and Clovis Oncology began working together clinically in July 2017. This partnership aims to evaluate the use of the combination of the drugs Opdivo (nivolumab) and Rubraca (rucaparib) in pivotal phase 3 clinical trials in multiple tumour types.
The infrastructure of the healthcare system is being modernised by governments in emerging nations, which is anticipated to expand access to healthcare. Therefore, government programmes to raise cancer awareness and the rising incidence in emerging nations are creating profitable business prospects.
The DNA Repair Drugs Market
is anticipated to be
dominated by North America. The region's market is expected to grow as a hub
for major businesses and as a result of early adoption of technologically
advanced items, new products will be introduced.
The market for DNA Repair Drugs
Market is
anticipated to be significantly dominated by Asia Pacific. During the
projection period, a significant rate of market growth is anticipated in the
area. Increased government activities, rising cancer prevalence, and increased
awareness are anticipated to drive market expansion in the area. For instance,
a paper in EC Gynaecology estimates that between 2012 and 2014, 4,818 new
instances of ovarian cancer were reported in India.
Top Companies Mentioned are- AstraZeneca Plc., Johnson &
Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc.,
Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc.,
Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui
Medicine Co., Ltd.
Comments
Post a Comment